Key Takeaways:
Sanofi and Regeneron’s Dupixent received European Union approval to treat chronic spontaneous urticaria in children aged 6 to 11, becoming the first targeted medicine for the condition in this age group.
"This approval represents a significant step forward for young children in the EU suffering from the debilitating symptoms of chronic spontaneous urticaria," a company spokesperson said.
The approval is based on a Phase 3 trial where Dupixent (dupilumab), when added to standard-of-care antihistamines, showed significant improvements in reducing itch and urticaria activity scores compared to antihistamines alone. The drug is jointly developed by Sanofi and Regeneron under a global collaboration agreement.
The decision on April 13, 2026, opens a new market for the blockbuster drug, potentially adding to future earnings for both companies and impacting analyst ratings. Dupixent is already approved for several other inflammatory conditions, including atopic dermatitis and asthma.
The expanded approval for Dupixent reinforces its position as a key growth driver for both Sanofi and Regeneron. Investors will be watching for the drug's sales performance in the new pediatric indication in the upcoming quarterly reports.
This article is for informational purposes only and does not constitute investment advice.
